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Next generation sequencingGenomics science has played a major role in the generation of new knowledge in the basic research arena,
and currently question arises as to its potential to support regulatory processes. However, the integration
of genomics in the regulatory decision-making process requires rigorous assessment and would beneﬁt
from consensus amongst international partners and research communities. To that end, the Global
Coalition for Regulatory Science Research (GCRSR) hosted the fourth Global Summit on Regulatory
Science (GSRS2014) to discuss the role of genomics in regulatory decision making, with a speciﬁc
emphasis on applications in food safety and medical product development. Challenges and issues were
discussed in the context of developing an international consensus for objective criteria in the analysis,
interpretation and reporting of genomics data with an emphasis on transparency, traceability and
‘‘ﬁtness for purpose’’ for the intended application. It was recognized that there is a need for a global path
in the establishment of a regulatory bioinformatics framework for the development of transparent,
reliable, reproducible and auditable processes in the management of food and medical product safety
risks. It was also recognized that training is an important mechanism in achieving internationally
consistent outcomes. GSRS2014 provided an effective venue for regulators and researchers to meet,
discuss common issues, and develop collaborations to address the challenges posed by the application
of genomics to regulatory science, with the ultimate goal of wisely integrating novel technical innova-
tions into regulatory decision-making.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).1. Introduction
We live in an era marked by signiﬁcant developments in the
advancement of new technologies and innovations in biomedical
and food safety research ﬁelds resulting in a dramatic increase in
our comprehension of genomics, biochemical mechanisms and
pathogen behavior. There is a plethora of new analytical tools;
some of these tools offer unprecedented high-throughput capabili-
ties that have revolutionized the way standard laboratory experi-
ments are performed. For example, microarray technologies
enable the testing of up to tens of thousands of hypotheses at
the DNA, RNA and protein levels in a single experiment (Schena
et al., 1995). Notwithstanding these rapid technological advances,
it may take years for the adoption and application of these innova-
tions in regulatory decision making processes. As depicted in Fig. 1,the translation process from innovation to application usually
takes several steps, often an interplay between science and percep-
tion. When a new technology is developed, its utility is primarily
assessed by non-regulatory entities, usually academia and product
development companies such as pharmaceutical entities. During
this process, the initial enthusiasm for the new technology gives
way to practical reality in a trial-and-error fashion. At the end of
this process, the regulatory community ﬁnally gains a better
understanding of the technology and how it can be used in a
‘‘ﬁt-for-purpose’’ manner in support of regulatory objectives.
While this vetting process is critical, it is not necessarily efﬁcient
or rapid. Therefore, one of the major challenges is an objective
approach to platforms and mechanisms expediting the innova-
tion-to-regulatory application pathway.
To facilitate this process, in 2010, the U.S. Food and Drug
Administration (FDA) launched its Advancing Regulatory Science
initiative aimed at developing ‘‘new tools, standards, and
approaches to assessing safety, efﬁcacy, quality, and performance
across FDA-regulated products’’ (http://www.fda.gov/downloads/
Fig. 1. An illustration of the innovation-to-application process. It usually takes 10–
20 years to translate innovation to regulatory application. Therefore, one of the
objectives of Regulatory Science Research is to expedite the translation process for
innovation by optimizing its reproducibility, standardizing the analysis protocols
and promoting data sharing.
Fig. 2. Pharmaceutical sales in emerging markets are forecasted to outpace US and
EU by 2020.
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The initiative identiﬁes eight scientiﬁc areas that affect multiple
regulated product domains. The guiding principle of the initiative
is to embrace the increased adoption of emerging technologies
such as genomics and bioinformatics in regulatory application. As
noted by the FDA commissioner (Hamburg, 2011): ‘‘Today, we
are neither effectively translating scientiﬁc discoveries into thera-
pies nor fully applying knowledge to ensure the safety of food and
medical products. We must bring 21st century approaches to 21st
century products and problems.’’ Regulatory science offers the
opportunity to bridge this translational gap.
The FDA, as well as regulatory agencies in other countries, rely
on science as the foundation for decision making to fulﬁll its mis-
sion (Woosley, 2013; FSANZ, 2013). Consequently, agencies such as
the FDA continuously evaluate new tools for their potential and
proper use in the review process. For example, advanced high
throughput genomic technologies offer new ways to study disease
and toxicity at the molecular level and for discovery of correspond-
ing biomarkers. Even when this technology was in its infancy, the
FDA had already started the discussion on how to evaluate these
new data streams in supporting the safety and efﬁcacy of new
medical products (Goodsaid et al., 2010) and how to develop stan-
dards for receiving these new data and ensuring reliable and repro-
ducible results (Tong et al., 2007).
Today’s consumer products are increasingly globalized, impact-
ing public health worldwide, posing new challenges for regulatory
authorities. For example, imports of drug products into the US have
tripled since 2002 (http://www.fda.gov/downloads/AboutFDA/
CentersOfﬁces/OfﬁceofGlobalRegulatoryOperationsandPolicy/Global
ProductPathway/UCM262528.pdf). The FDA currently regulates
300,000 production facilities in 150 different countries. As shown
in Fig. 2, global pharmaceutical sales in emerging markets are
anticipated to outpace sales in the US and EU by 2020, in contrast
to sales in 2010. Regulatory science must confront these new reali-
ties and take an approach that emphasizes global partnerships to
evaluate new technologies for regulatory application. More speciﬁ-
cally, countries need to work together as partners and collaborate
in the development of the tools and adopt technologies needed by
regulatory authorities throughout the world.
To that end, the Global Coalition for Regulatory Science Research
(GCRSR) was established in 2013 as an initiative of the FDA
(Howard et al., 2013; Miller et al., 2013; Slikker et al., 2012) and
now involves a broad range of countries and regions. The missionof GCRSR is to foster the uptake of emerging technologies by engag-
ing global regulatory agencies. This international coalition has the
objectives of facilitating education, scientiﬁc training and scientiﬁc
exchanges in the ﬁeld of regulatory science. It focuses on research
to support regulatory decision making by identifying and promot-
ing best practices to understand and interpret data from innovative
technologies such as genomics. To date, GCRSR discussions have
been focused on (1) deﬁning the role of global research collab-
orations in advancing regulatory science and its impact on public
health; (2) exploring the future of Regulatory Science Research as
a tool for advancing regulatory science in the areas of food safety
and medical products; and (3) developing strategies for training
regulatory scientists in a global setting. Consequently, its main
activities involve (1) holding workshops and scientiﬁc meetings
to discuss the development of new technologies and their potential
application in regulatory settings; (2) exchanging scholars and stu-
dents for the purpose of providing education and training; and (3)
enhancing the development and use of regulatory science princi-
ples. To achieve these goals, the annual Global Summit on
Regulatory Science (GSRS) meeting has been instituted. GSRS con-
ferences provide a venue for regulators and researchers tomeet and
develop collaborations that address the challenges and needs in the
interest of advancing regulatory science. Four meetings have been
conducted so far, with the ﬁrst (GSRS2011) taking place in the US
(Slikker et al., 2012), the second (GSRS2012) in China (Miller
et al., 2013), the third (GSRS2013) in the US (Howard et al.) and
the fourth (GSRS2014) in Canada (http://www.fda.gov/AboutFDA/
CentersOfﬁces/OC/OfﬁceofScientiﬁcandMedicalPrograms/NCTR/
WhatWeDo/ucm289679.htm). Here we summarize key discussions
from the most recent summit, GSRS2014, which took place in
Montreal, Canada, on August 21–22, 2014, and focused on the
current and future role and challenges of applying genomics in a
regulatory context.2. Genomics in regulatory science – A key focus of GSRS2014
Genomics has attracted widespread attention as an advanced
means of studying the underlying molecular mechanisms of dis-
ease progression, health and pathogen behavior and relationships.
It has also gained attention as an applied discipline to identify
novel molecular targets and disease markers for drug development
and/or diagnostic purposes, and to address regulatory challenges
that are difﬁcult to overcome by conventional methods.
Genomics is recognized in the FDA Advancing Regulatory Science
(http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/
RegulatoryScience/UCM228444.pdf) strategy as well as by reg-
ulatory agencies in other countries as a major opportunity for
advancing food safety, medical product development (in terms of
safety and efﬁcacy), and precision/personalized medicine. Despite
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the anticipated beneﬁts have been slow to translate into regulatory
applications. While the reasons for this slow uptake are multi-fac-
torial, the need for further knowledge discovery and the develop-
ment of more sophisticated tools to query large data sets are
necessary. Perhaps as importantly, the adoption of new genomic
technology hinges on the creation of regulatory global partnerships
to collaborate, share expertise and determine the extent to which
emerging genomics technologies might beneﬁt and serve common
regulatory needs. Determining the safety, efﬁcacy, quality, potency
and performance of medical products and foods is required by law
in the U.S as well as in many other countries. Therefore, the
emphasis of GSRS2014 was to address key questions regarding
the application of genomics for safety assessments of foods and
medical products, and how these questions can be appropriately
addressed via collaboration and cooperation in the global context.
These questions include (1) the role of genomics in advancing reg-
ulatory science in the areas of medical products and food safety;
(2) the issues and challenges of applying next-generation sequenc-
ing to pathogen detection, identiﬁcation and characterization; and
(3) the role of bioinformatics in advancing regulatory genomics.
The theme of GSRS2014 was ‘‘Regulatory Genomics and
Beyond.’’ The meeting consisted of four sessions featuring panels
of subject matter experts speaking on various themes: session 1,
‘‘Genomics and Product Safety,’’ provided a global overview of
genomic applications in food safety and medical products among
regulatory agencies worldwide; session 2, ‘‘Lessons Learned from
Applying Genomics to Food Program,’’ emphasized how genomics
can enhance regulatory capacity and efﬁciency for food safety; ses-
sion 3, ‘‘Challenges in Regulatory Genomics,’’ discussed challenges
in applying genomics, particularly next-generation sequencing
technologies for pathogen identiﬁcation and outbreak detection;
and session 4, ‘‘Genomics and Beyond,’’ examined a broad range
of topics relating to regulatory genomics, including how to regulate
genomics-based diagnostic devices, and the ethical issues and
dilemmas faced in genetic testing and policy development. The
conference concluded with a panel discussion on (1) how reg-
ulatory practices and approaches should be developed around
new genomics technologies; and (2) the best practices and guide-
lines for emerging genomics programs in regulation.3. Regulatory genomics in food safety and medical products
The role of genomics in food safety through whole genome-se-
quencing (WGS) was a major theme of GSRS2014. The discrim-
inatory power of WGS approaches in food safety has been
increasingly appreciated by regulatory food safety agencies around
the world, especially in outbreak recognition and source attribu-
tion. Recent advancements in WGS such as next-generation
sequencing (NGS) technologies open new possibilities for compre-
hensive analyses of microbes recovered from inspection samples. It
was pointed out that NGS can now render a bacterial genome
much faster (i.e., within a working day) and at a signiﬁcantly lower
cost (e.g., less than $100 USD with MiSeq systems by Illumina,
www.illumina.com/systems/miseq.html) than previously possible,
making it feasible to sequence food-borne isolates in nearly real-
time under certain circumstances (e.g., during food-borne illness
outbreak investigations). Presenters from regulatory agencies of
various countries (e.g., the US FDA’s Center for Food Safety and
Applied Nutrition and Canadian Food Inspection Agency and
Public Health Agency of Canada) outlined the promising regulatory
roles of WGS in food microbiology inspection programs including,
but not limited to, pathogen identiﬁcation, outbreak detection,
source attribution, and hazard characterization.In the course of the ensuing discussions, various challenges to
the full implementation of WGS in regulatory food safety applica-
tions were recognized. As with conventional microbiological typ-
ing tools, genomic applications have also had to undergo
substantial evaluations for reliability and reproducibility as they
are integrated into regulatory decision-making processes.
Although processes can always be improved, studies of this nature
have shown that whole genome sequencing is ﬁt for purpose for
foodborne pathogen traceability and have included proﬁciency
across a distributed network of end-users, evaluation of consis-
tency across various sequencing platforms, and validation of the
bioinformatics pipelines deployed to cluster resultant ‘‘big data’’.
The U.S. FDA’s GenomeTrakr Network represents one example of
a distributed network of next-generation DNA sequencers that is
focused on enhancing food safety. In many ways, the current para-
digm shift in molecular subtyping to genomic approaches has been
reminiscent of the challenges faced by FDA and other federal public
health agencies during previous deployments of subtyping tools
such as pulsed-ﬁeld gel electrophoresis (PFGE) which remains in
use still today by many laboratories.
One important outcome of GSRS2014 is recognition that geno-
mics science is rapidly evolving and progressing, and that there
are already examples of its utilization in support of regulatory food
safety investigations worldwide. By contrast, standardization of
regulatory practices with new technologies and interpreting the
information which is derived from them may take more time.
Therefore, the question was raised about how regulatory practices
and standards should cope with the fast paced evolution of WGS
technology. This issue needs to be addressed at multiple levels
such as development of standard practices, data sharing and train-
ing. Some argued that such a challenge should not be a barrier to
the use of genomics in regulation. The ability to discern the entire
genetic blueprint of a foodborne bacterial isolate by WGS offers an
unprecedented level of detailed analysis not achievable using con-
ventional techniques such as PFGE, PCR and even microarrays, pro-
viding enhanced discriminatory power and new opportunities for
assessing the safety of products. The general consensus at the
meeting was that this powerful new technology should be fully
embraced to execute the most comprehensive analyses leading
to the generation of highly informative test results to underscore
regulatory decisions. To uphold this vision, it is of great importance
that the procedures and processes used to inform risk management
decisions be transparent, reliable, reproducible and auditable.
While microbial genomics (including antimicrobial resistance)
and food safety received signiﬁcant attention in GSRS2014, the role
of genomics inmedical product development and approval was also
discussed. There was a particular emphasis on issues relating to
applicability of genomics in personalized (aka precision) medicine.
As drug makers move toward the development of therapeutics
requiring knowledge of the patient’s genetic make-up, there will
be a greater demand for technology innovation, underscoring the
need for increased partnerships between the private sector,
academia and regulatory agencies. Pharmacogenomics (PGx) offers
the potential to discover new biomarkers for product safety and
efﬁcacy to enhance regulatory science. PGx is deﬁned as ‘‘the study
of variations of DNA and RNA characteristics as related to drug
response’’ (http://www.ema.europa.eu/docs/en_GB/document_
library/Scientiﬁc_guideline/2009/09/WC500002880.pdf) and the
FDA has incorporated many such biomarkers in drug labels (http://
www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/
ucm083378.htm). Speakers discussed various regulatory applica-
tions of PGx biomarkers with the recognition that some challenges
remain such as how to assess the body of scientiﬁc evidence to sup-
port including a PGx biomarker in drug labels and how to qualify a
PGx biomarker for regulatory application (Otsubo et al., 2013). It
was recognized that, in some cases, a PGx biomarker relevant to
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biomarker qualiﬁcation should carefully consider the weight-
of-evidence approach in deﬁning ﬁt-for-purpose applications,
which has been emphasized in biomarker qualiﬁcation programs
by FDA (http://www.fda.gov/downloads/drugs/guidancecomplian
ceregulatoryinformation/guidances/ucm230597.pdf) and European
Medicines Agency (http://www.ema.europa.eu/docs/en_GB/
document_library/Regulatory_and_procedural_guideline/2009/10/
WC500004201.pdf). One challenge of identifying a PGx biomarker
suitable for regulatory applications is the fact that we are often in
a ‘‘shades of grey’’ situation with respect to genotype-phenotype
correlation (Lu et al., 2014), which gives rise to signiﬁcant complex-
ity in linking a PGx biomarker to disease manifestation and/or
treatment response. Thus, translating PGx data to clinical utility
and drug development requires a strong regulatory science
‘‘bridge’’ that consists of reproducible methodologies to generate
reliable data, standard data analysis protocols and consensus
within the community to prioritize key factors contributing to dis-
ease and drug response.4. Key issues and challenges in regulatory genomics – A path
forward
The GSRS2014 speakers and participants emphasized the
importance of bioinformatics as an essential tool in the application
of genomics technology in regulatory science. In past decades, both
drug development and food safety evaluation have undergone a
paradigm shift through substantial investments in genomics plat-
forms to support investigations of disease and toxicity at the
molecular level. In addition, the rapid growth of biomedical data
and their availability through public domains provides unprece-
dented opportunities for data mining and knowledge base devel-
opment to generate new hypotheses and guide experiment
designs. These types of data are both voluminous and noisy in con-
tent, requiring bioinformatics solutions to extract useful knowl-
edge through data management, analysis, interpretation and the
establishment of standards to uphold the integrity of these opera-
tions. Speciﬁcally, data management strategies should include pro-
visions for long term storage of data to ensure its integrity for legal
purposes and retrospective analyses. It was recognized that the
assessment of bioinformatics is a complex task requiring signiﬁ-
cant resources which may be beyond the capacity of individuals
to pursue alone. One approach to ensure that appropriate tools
are available to all interested parties is to develop consensus
among regulatory agencies participating in the GCRSR for the stan-
dardization of data management and analysis practices to promote
transparency and reproducibility of processes underscoring reg-
ulatory decision making. To that end, the GCRSR bioinformatics
working group was charged with developing a scientiﬁc program
focusing on bioinformatics for GSRS2015. Moreover, a technical
group governed by the GCRSR bioinformatics working group has
undertaken an initiative to determine a best practices approach
for the application of bioinformatics in food safety.
Training as a principle means for advancing regulatory science
was mentioned at the conference by many speakers and in the
panel discussion session. It was well appreciated that genomics
is complex, rapidly evolving, and results in the generation of big
datasets requiring bioinformatics support. Therefore, there is a
need to implement diverse training opportunities to develop skill
sets with an iterative process for both regulators and regulated
industries. The participants of GSRS14 were introduced to the
International Scientists Exchange Program (ISEP). ISEP was devel-
oped in support of the US-FDA’s regulatory capacity strengthening
efforts and provides an opportunity for researchers from develop-
ing countries to conduct regulatory research projects at the FDA.The research training experience is focused on learning concepts,
skills, and techniques that are critical for scientists to build the
regulatory infrastructure needed to be successful in the global
context. ISEP enhances the quality of education for scientists
through international exchange while exploring the international
dimensions of their academic ﬁeld and promotes international
understanding and cross-cultural learning for mentors and partici-
pants. The projects offered to participants are designed to teach
basic research techniques, i.e., core competencies including lab-
oratory safety, study design, ethics in research, bioinformatics,
and data integrity. Sharing information and offering training cur-
ricula and technology is critical in supporting the need and
improvement of global public health. Training scientists via the
GCRSR model is an important step toward advancing regulatory
science globally.5. Summary
The world just observed the 10-year anniversary of the
sequencing of the human genome (Venter, 2011). No previous
scientiﬁc accomplishment has been as celebrated for its potential
to improve human health. Despite the initial excitement and pro-
mise, and a decade of further research and technical advancement,
the anticipated beneﬁts have been slow to impact the regulatory
stage to a signiﬁcant degree. The fulsome exploitation of the blue-
print of life will demand continued innovation in technology as
well as an enhanced nurturing of regulatory science. The
GSRS2014 served as a venue for an important dialogue on the role
of genomics in regulatory science and the role of regulatory science
in advancing the uptake of genomics. The participants acknowl-
edged the importance of developing regulatory practices and pro-
cedures to facilitate application of genomics science on the
premise that application of the best science results in the best
quality of regulation. To realize the beneﬁt of this ‘‘symbiotic
relationship’’ between genomics and regulatory science, we need
to overcome many challenges. Some challenges are technical in
nature, such as data sharing, analytical protocols and development
of standardized protocols. Other challenges are of a logistical nat-
ure and can be effectively addressed through GCRSR initiatives
such as training programs to support rapid translation of basic
science to regulatory application. A distinction in regulatory
science roles was recognized in the application of genomics for
either food safety or medical products. For the former, the empha-
sis is on developing principles for pathogen genomics to under-
score an enhanced regulatory process of pathogen identiﬁcation
and outbreak detection, while the latter focuses more on develop-
ing review principles for the new data stream and its application to
personalized medicine and biomarkers. Regardless of the applica-
tion, the GSRS2014 focused on Regulatory Science Research
through embracing a novel thinking process for the effective use
of the new genomics analytical paradigm.Disclaimer
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